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Abstract
Importance—Breast magnetic resonance imaging (MRI) is increasingly used for breast cancer
screening, diagnostic evaluation, and surveillance However, we lack data on national patterns of
breast MRI use in community practice.
Objective—To describe 2005–2009 patterns of breast magnetic resonance imaging (MRI) use in
U.S. community practice.
Design—Observational cohort study
Setting—Data collected from 2005–2009 on breast MRI and mammography from five national
Breast Cancer Surveillance Consortium registries.
Participants—Data included 8931 breast MRI examinations and 1,288,924 screening
mammograms from women aged 18–79 years.
Main measures—We calculated the rate of breast MRI examinations per 1000 women with
breast imaging within the same year and described the clinical indications for the breast MRI
examinations by year and age. We compared women screened with breast MRI to women
screened with mammography alone for patient characteristics and lifetime breast cancer risk.
Results—The overall rate of breast MRI from 2005 through 2009 nearly tripled from 4.2 to 11.5
examinations per 1000 women with the most rapid rise from 2005–2007 (p=0.02). The most
common clinical indication was diagnostic evaluation (40.3%), followed by screening (31.7%).
Compared to women who received screening mammography alone, women who underwent
screening breast MRI were more likely to be <50 years, white non-Hispanic, nulliparous, and have
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extremely dense breast tissue, a family history of breast cancer, and a personal history of breast
cancer. The proportion of women screened by breast MRI at high lifetime risk for breast cancer
(>20%) increased during the study period from 9% in 2005 to 29% in 2009.
Conclusions and relevance—Use of breast MRI for screening in high-risk women is
increasing. However, our findings suggest there is a need to improve appropriate utilization,
including among women who may benefit from screening breast MRI.
INTRODUCTION
In 2012, women in the United States underwent nearly 39 million mammograms.1,2
However, breast magnetic resonance imaging (MRI) is increasingly used for breast cancer
screening, diagnostic evaluation, and surveillance.3,4 Mammography remains the key
imaging tool for population-based screening5 and for work-up of women experiencing breast
symptoms,6 but breast MRI is becoming more common in community settings.3,7,8 The
benefit of breast MRI includes high sensitivity for identifying clinically occult breast
malignancy.6 However, compared to mammography, breast MRI has a modest specificity
that leads to higher false positive rates;9,10 it is also more expensive and requires
intravenous contrast medium.
National guidelines support breast MRI for particular clinical indications. The most widely
accepted guideline, from the American Cancer Society (ACS) in 2007, is to screen
asymptomatic women at high risk for breast cancer defined as: 1) known BRCA gene
mutation carriers; 2) first-degree relatives of a known BRCA gene mutation carrier who are
themselves untested; or 3) women with >20% lifetime risk of breast cancer, according to
risk assessment tools based on family history of breast cancer.11,12 The ACS lacked
sufficient evidence to make recommendations for women in other risk subgroups. The
National Comprehensive Cancer Network (NCCN) recommends considering the use of pre-
operative breast MRI for women with a new breast cancer diagnosis to determine the extent
of disease before surgery in occult tumors, although there is not a broad consensus.6
Despite the rapid expansion of breast MRI in different settings and for multiple clinical
applications, most published reports on its use are from single institutions3,7 and focus only
upon specific populations.7,8 We lack data on national patterns of breast MRI use in
community practice.
Our purpose was to evaluate patterns of breast MRI use among community-based facilities
across the U.S.. Using data from 2005 through 2009 from five registries in the Breast Cancer
Surveillance Consortium (BCSC),13 we evaluated rates and distributions of clinical
indications for breast MRI temporally and by age. We also compared characteristics of
women screened with breast MRI to women who were screened with mammography alone.
METHODS
Study registries
The BCSC is a collaboration of breast imaging registries in community-based settings with
linkages to tumor and/or pathology registries. The BCSC is supported by a Statistical
Coordinating Center (SCC). The goals of the BCSC are to assess the delivery and quality of
U.S. breast cancer imaging and patient outcomes. This study used data from five registries:
Carolina Mammography Registry, Group Health Cooperative (Washington State), New
Hampshire Mammography Network, San Francisco Mammography Registry, and Vermont
Breast Cancer Surveillance System.13 The data from these five registries reflect
mammography practice as it is performed in the community and are located in counties that
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contain slightly more than 5% of the nation's population.14 Each registry and the SCC
received institutional review board approval for either active consent or passive permission
or a waiver of consent to enroll participants, link study data, and perform analytic studies.
All procedures are Health Insurance Portability and Accountability Act compliant. All
registries and the SCC have received a Federal Certificate of Confidentiality and other
protection for the identities of women, physicians, and facilities that are subjects of this
research.
BCSC data are collected as part of routine clinical care at the time of imaging from patients
and radiologists. Mammography data include indication for the mammogram and American
College of Radiology Breast Imaging Reporting and Data System (BI-RADS) assessment
and breast density.15 Each registry site sends their data to the SCC for pooling and statistical
analysis. All data undergo rigorous quality control checks.
Breast MRI data
We used data on breast MRI conducted in 2005–2009 on women aged 18–79 years old. Data
were obtained from registries retrospectively and prospectively using electronic radiology
data systems (64%), chart abstraction of radiology reports (20%), completion of advanced
imaging form at time exam (16%), and billing codes (0.02%). For each examination,
standardized information was recorded including the clinical indication for the breast MRI,
BI-RADS assessment, and clinical recommendations (e.g., routine mammographic follow-
up, follow-up breast MRI in 6 months, or biopsy). To evaluate potential bias due to
incomplete data capture from BCSC facilities, the registries surveyed BCSC facilities to
estimate data capture for breast MRI examinations. Facilities estimated completeness of
recording breast MRI data as none, <50%, 50–89%, or ≥90%.
The majority of examinations were coded with a single indication (89%). In the 11% of
breast MRI examinations with >1 indication (up to 3 could be coded), we categorized
clinical indication using the following hierarchy to isolate true screening breast MRI
examinations in asymptomatic women: 1) evaluation of extent of disease in patients with a
recent breast cancer diagnosis; 2) evaluation of response to neoadjuvant chemotherapy; 3)
axillary adenopathy (malignant) of unknown primary; 4) additional evaluation of recent
mammogram or other non-MRI breast imaging; 5) evaluation of breast problem (i.e.,
symptomatic); 6) recurrence vs. scar; 7) short interval follow-up of prior breast MRI
examination; 8) screening (i.e., asymptomatic); 9) evaluation of implants; and 10) other. For
example, if an examination was coded as additional evaluation of a recent mammogram and
screening, the indication was coded as additional evaluation of a recent mammogram. For all
examinations, primary indications were combined into four broader groups: cancer staging/
treatment (groups 1–3), diagnosis (groups 4–6), screening including surveillance (group 8),
and other (groups 7, 9–10).
Patient characteristics
At the time of mammography, women completed a questionnaire to ascertain age, race/
ethnicity, first-degree family history of breast cancer, history of breast procedures, and other
risk factors. For breast MRI examinations, women typically did not complete an additional
patient questionnaire. Therefore, we linked the breast MRI examination to the most recent
patient questionnaire completed at a mammography visit within the prior 12 months (median
number of days=87).
History of prior mammography within 12 months was calculated based on mammography
receipt within BCSC data. A personal history of breast cancer was documented through
either self-report or linkage with BCSC pathology and cancer registry data. BI-RADS breast
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density was obtained from the most recent mammogram. If breast density measures were
missing from the most recent mammogram, the next mammogram within 18 months
informed the missing breast density measure and no change in hormone therapy use and
incident breast cancer diagnosis. Finally, for each woman without a personal history of
breast cancer, we calculated lifetime breast cancer risk based on the National Cancer
Institute Breast Cancer Risk Assessment Tool (BCRAT; http://www.cancer.gov/
bcrisktool/).16–20 The BCRAT includes age, race, previous breast biopsies, presence of
atypia, age at menarche, age at first live birth, and history of breast cancer in first-degree
relatives. Risk was categorized as <15%, 15–20%, and >20%, to correspond to cutoffs in the
ACS guidelines for breast screening with MRI.11
Statistical Analysis
We identified 9537 breast MRI examinations in 2005–2009. We excluded 606 (6.4%)
examinations with missing data on clinical indication. The final sample was 8931 breast
MRI examinations from 6777 individual women (range 1–13 exams per woman). About
92% of the breast MRI data are from facilities with >90 data capture. We calculated the total
number of breast MRI examinations by year and the distribution by clinical indication, year
of exam, and 10-year age groups. We calculated annual breast MRI rates as the number of
breast MRI examinations per 1000 women with any breast imaging within the same year
from facilities reporting >90% data capture of breast MRI examinations. Rates were
calculated for overall breast MRI use and according to clinical indication. We used a linear
regression model to test for trends in the rates of breast MRI use over time by 2005–2007
and 2007–2009.
We compared patient characteristics, combinations of characteristics and BCRAT lifetime
risk scores among women screened with breast MRI (n=2,831 examinations) to women
screened with mammography alone (n=1,288,924 examinations). We present the distribution
of patient characteristics by all women and restricted to women with no prior breast cancer
history. Differences in patient characteristics were calculated using a chi-squared test. In a
sensitivity analysis, we restricted imaging data to facilities reporting >90% data capture of
breast MRI examinations.. As the results were similar, we present the overall findings for all
imaging examinations rather than the restricted sample. All analyses were performed using
SAS® Version 9.2 (SAS Institute, Cary, NC), and two-sided p<0.05 was considered
statistically significant.
Results
Patterns of breast MRI use, 2005–2009
From 2005 through 2009, the rate of breast MRI use increased from 4.2 to 11.5
examinations per 1000 women (Figure 1). The steepest rise in use occurred from 2005–2007
with an increase of 5.8 MRI examinations per 1000 women per year (p=0.02) compared to
only 1.5 additional examinations per year from 2007–2009 (p=0.45). Through 2007, the
most common use of breast MRI was diagnostic work-up for a positive finding. The rate of
screening breast MRI increased more than four-fold between 2005 and 2007 from 0.8 to 3.4
per 1000 women, and then remained fairly stable at 4.3 breast MRI examinations per 1000
women in 2009.
The total number of breast MRI examinations per year increased from 863 in 2005 to 2264
in 2007. From 2007–2009, the number of exams per year remained stable at approximately
2150 (Table 1). Across the five-year study period, the most common indications were
diagnostic work-up of a non-MRI or clinical finding (40.3%), screening (31.7%), cancer
staging/treatment (16.3%) and other (11.8%).
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The proportion of examinations with an indication of diagnostic work-up decreased from
53.2% in 2005 to 34.8% in 2009. The single most common indication contributing to the
diagnostic work-up classification was evaluation of a prior non-MRI finding. The proportion
of examinations attributed to screening increased from <20% in 2005 to 34.5% in 2009.
Evaluation for cancer staging and treatment, primarily among newly diagnosed women,
remained fairly constant over the study period at 15–18% of all examinations.
Across all ages, use of breast MRI for diagnostic purposes was the most common indication,
with the highest proportion in the oldest women in our study (70–79 years) (Table 2).
Screening accounted for 34.3% of MRI examinations in women <50 years compared to
17.8% in women aged 70–79 years. Proportions for other indications were similar across age
groups.
Comparison of patient characteristics by screening breast MRI vs. mammography alone
Compared to women screened for breast cancer by mammography alone, women screened
by breast MRI were significantly more likely to be younger (<50 years), white non-
Hispanic, or nulliparous; they were more likely to have a first degree relative with breast
cancer, prior breast biopsy, or extremely dense breast tissue (Table 3). Women who received
screening breast MRI were also more likely to have a personal history of breast cancer
(44.9%) compared to women who received mammography alone (4.7%) (p<0.0001). When
we restricted our evaluation to women without a personal history of breast cancer, the
distribution of characteristics did not substantially change with two exceptions. Among
women without a personal history of breast cancer, screening breast MRI was used by
significantly fewer women with a prior breast biopsy but significantly more women with a
family history of breast cancer compared to women who received mammography alone.
Women with combinations of prior breast biopsy, positive family history, and extremely
dense breast tissue were more likely to be screened by breast MRI. About one-third of all
breast MRI for screening was in women with both a prior breast biopsy and positive family
history (p<0.0001), regardless of personal history of breast cancer.
Among women who received screening breast MRI, 25% had a >20% lifetime risk of
developing breast cancer according to the BCRAT model and 53% had <15% lifetime risk,
compared to women who received mammography alone, where 2% had a lifetime risk of
>20% and 92% had a lifetime risk of <15% (Table 4). The proportion of women at high risk
for breast cancer who received breast MRI for screening increased from 9% in 2005 to 29%
in 2009 (test for trend p<0.0001). No change by risk status over the study period was seen in
women screened by mammography alone. Over the five year study period, 25,237 women
who were screened with mammography alone had a >20% lifetime breast cancer risk.
DISCUSSION
Our study describes the patterns of breast MRI use in U.S. community practice, the setting
in which most women receive breast imaging. Our results confirm a rise in the use of breast
MRI from 2005–2007. Up to 2009, rates of use remained constant overall and across all
clinical indications. Other reports demonstrated an increase in use of breast MRI3,7 without
observing a plateau in utilization rates.
During our study period, the most common use of breast MRI was for diagnostic evaluation
of a non-MRI finding. We could not determine if these examinations were performed to
avoid biopsy of a suspicious clinical finding or to plan for a subsequent biopsy. Use of
breast MRI to avoid biopsy does not have a sufficiently high negative predictive value to
warrant its use for this purpose, particularly given the relatively low pretest probability of
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malignancy (∼2%) above which biopsy is performed as standard practice.21 Over the study
period, the use of breast MRI for diagnostic work-up diminished. By 2009, the rate of breast
MRI for diagnosis was similar to the rate for screening, which was the second most common
indication overall.
We determined that several patient characteristics were associated with use of screening
with breast MRI, which confirms findings by Miller et al22 suggesting increased use among
women with a family history or personal history of breast cancer. We detected that younger,
white women were more likely to receive breast MRI for screening, which differed from
Miller et al who found that older, black women were more likely to receive breast MRI.22
Differences in our results might be explained by our examination of screening breast MRI
compared to Miller’s attention to breast MRI for any clinical indications Also, women who
had a prior breast biopsy and a positive family history were more likely to receive breast
MRI than mammography alone, demonstrating two factors which influence patient care.
Of the women screened with breast MRI, 45% had a personal history of breast cancer. For
the remaining 55%, we used the BCRAT model to determine whether breast MRI use
reflected the national recommendations that women at high risk lifetime of breast cancer
receive screening breast MRI as an adjunct to mammography. We determined that only 25%
of women screened with breast MRI were considered high lifetime risk (>20%). The
majority of women receiving screening breast MRI were at intermediate lifetime breast
cancer risk (15–20%), for which evidence for breast MRI screening is insufficient, or
average risk (<15%), for which screening breast MRI is not recommended. No evidence
suggested that the overall rate of screening breast MRI increased after the ACS
recommendation in 2007, although the proportion of women at high risk for breast cancer
who received breast MRI for screening increased over the five-year study period. Overall,
<5% of women with >20% lifetime risk received breast MRI for screening. Current patterns
suggest there was improvement in clinical alignment with breast screening guidelines.
Several possibilities might explain why women with only an average lifetime breast cancer
risk are screened by breast MRI. Some women with lifetime breast cancer risk scores <20%
might have indications for screening breast MRI that were not captured in our data (e.g.,
BRCA mutation, first-degree relative with BRCA mutation, or prior chest radiation).
However, these are unlikely to account for a substantial portion of the women at lower risk
but undergoing screening MRI, as they are relatively rare in the general population. Another
possible reason is misperception about breast cancer risk. Both women and physicians
overestimate a woman’s lifetime risk of breast cancer,23,24 and inaccurate perceptions about
risk can arise in the absence of clear risk counseling. Both younger and older women
estimate their lifetime risk of breast cancer as approximately 18–20% higher than their
actual risk,23 and women who are at average risk are more likely to overestimate their risk
than high-risk women.24 Physicians might base their estimate of high-risk on report of
family history alone without using a risk calculator.25 Also, women with dense breast might
also be receiving breast MRI due to low sensitivity of screening mammography in dense
breast tissue.26 Our data suggest increased use of breast screening MRI by combinations of
risk factors, which are easily assessed by providers.
Also, clinically important were the women—about 25,200 in our study sample—who had a
>20% lifetime risk of breast cancer but were screened by mammography alone. ACS and
NCCN guidelines recommend breast MRI screening with screening mammography for
women at high-risk for breast cancer. Brinton et al. documented that women with a high
lifetime breast cancer risk do not fully adopt screening with breast MRI, and have a low
overall rate of adherence to guidelines.27 Berg and colleagues evaluated reasons that high-
risk women refuse breast MRI and found the most common were claustrophobia, time
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constraints, financial concerns, a physician who did not provide referral or believe MRI was
warranted, and lack of patient interest.28 Additional issues could be availability of breast
MRI outside of urban/academic areas or providers who do not assess breast cancer risk. Our
study did not address why women received a particular type of imaging.
Strengths of our study are that it provides the only multi-facility evaluation of breast MRI
utilization patterns across US community practice. Although data were from five BCSC
registries from a variety of community-based practice facilities across the United States,
there remain some limitations. First, women from BCSC registries might have different
patient characteristics than women outside the BCSC; however, when we restricted to
facilities with sufficient data capture, there were no differences in the distribution of patient
characteristics in our sensitivity analysis. Second, our data are reported in aggregate and we
did not evaluate geographic variation. Therefore, we could not evaluate disparities in access
to care, which contribute to determining who receives advanced technologies.8 The
reporting of indication for breast MRI examinations could differ across contributing
registries, which could lead to heterogeneity in examination indication. To address this, we
reviewed the indications for exams and created a hierarchy to identify true screening. Our
study data included documented clinical indication, an improvement over studies using
claims-based registries with no data on exam indication. Finally, we used the BCRAT model
to estimate lifetime risk in our population. Although the ACS recommends classification
with a familial-based model, this was not possible with our data. There are discrepancies in
the reporting of lifetime risk of breast cancer as reported by Ozanne et al. who demonstrated
inconsistency in three familial-based risk models that put women in different categories with
differential overlap.29
Our rapidly changing healthcare environment demands that we frequently, accurately, and
comprehensively evaluate the diffusion of new technology into community practice,
including how often technology is being used and for what clinical indications Our findings
suggest there have been improvements in appropriate use of breast MRI, with fewer exams
performed for further evaluation of abnormal mammograms and symptomatic patients, and
more breast MRI performed for high risk screening. We also identified a need for more
appropriate risk-based use of breast MRI as a screening examination, as we identified
women at average risk receiving MRI and women at high risk not receiving MRI. Our
findings suggest there is a need for improvement in use of diagnostic and screening breast
MRI for women most likely to benefit from this imaging tool.
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FIGURE 1.
Temporal trends in breast MRI rates per 1000 women overall and by clinical indication
(from the Breast Cancer Surveillance Consortium, 2005–2009).
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TABLE 2
Proportion of 2005–2009 breast MRI examinations by clinical indication and stratified by age.
Total
N (%)
Age <40 940
Diagnostic 370 (39.4)
Screen 322 (34.3)
Staging/Treatment 136 (14.5)
Other 112 (11.9)
Age 40–49 2,655
Diagnostic 1,026 (38.6)
Screen 924 (34.8)
Staging/Treatment 385 (14.5)
Other 320 (12.1)
Age 50–59 2,943
Diagnostic 1,123 (38.2)
Screen 968 (32.9)
Staging/Treatment 483 (16.4)
Other 369 (12.5)
Age 60–69 1,742
Diagnostic 756 (43.4)
Screen 501 (28.8)
Staging/Treatment 300 (17.2)
Other 185 (10.6)
Age 70–79 651
Diagnostic 321 (49.3)
Screen 116 (17.8)
Staging/Treatment 147 (22.6)
Other 67 (10.3)
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